Restoration of conformation of mutant p53

Ann Oncol. 2018 May 1;29(5):1325-1328. doi: 10.1093/annonc/mdy057.
No abstract available

MeSH terms

  • Alkylation / drug effects
  • Aminoquinolines / pharmacology
  • Aminoquinolines / therapeutic use
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Clinical Trials as Topic
  • Ellipticines / pharmacology
  • Ellipticines / therapeutic use
  • Humans
  • Mutation
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Protein Binding
  • Protein Interaction Domains and Motifs / drug effects*
  • Protein Interaction Domains and Motifs / genetics
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use
  • Quinuclidines / pharmacology
  • Quinuclidines / therapeutic use
  • Structure-Activity Relationship
  • Thiosemicarbazones / pharmacology
  • Thiosemicarbazones / therapeutic use
  • Tumor Suppressor Protein p53 / chemistry
  • Tumor Suppressor Protein p53 / drug effects*
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • 1-methyl-4-phenyl-3 -(1H-pyrrol-1-yl)-1H-pyrazole
  • 3-(9-methoxy-5,11-dimethylpyrido(4,3-b)carbazol-6-yl)propan-1-amine
  • Aminoquinolines
  • Antineoplastic Agents
  • COTI-2 compound
  • Ellipticines
  • Pyrazoles
  • Pyrroles
  • Quinuclidines
  • TP53 protein, human
  • Thiosemicarbazones
  • Tumor Suppressor Protein p53
  • eprenetapopt